A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
06 2019
Historique:
received: 06 10 2018
accepted: 28 02 2019
pubmed: 30 3 2019
medline: 6 10 2020
entrez: 30 3 2019
Statut: ppublish

Résumé

Current literature suggests that several pathophysiological factors and mechanisms might be responsible for the nonspecific symptom complex of overactive bladder (OAB). To provide a comprehensive analysis of the potential pathophysiology underlying detrusor overactivity (DO) and OAB. A PubMed-based literature search was conducted in April 2018, to identify randomised controlled trials, prospective and retrospective series, animal model studies, and reviews. OAB is a nonspecific storage symptom complex with poorly defined pathophysiology. OAB was historically thought to be caused by DO, which was either "myogenic" (urgency initiated from autonomous contraction of the detrusor muscle) or "neurogenic" (urgency signalled from the central nervous system, which initiates a detrusor contraction). Patients with OAB are often found to not have objective evidence of DO on urodynamic studies; therefore, alternative mechanisms for the development of OAB have been postulated. Increasing evidence on the role of urothelium/suburothelium and bladder afferent signalling arose in the early 2000s, emphasising an afferent "urotheliogenic" hypothesis, namely, that urgency is initiated from the urothelium/suburothelium. The urethra has also recently been regarded as a possible afferent origin of OAB-the "urethrogenic" hypothesis. Several other pathophysiological factors have been implicated, including metabolic syndrome, affective disorders, sex hormone deficiency, urinary microbiota, gastrointestinal functional disorders, and subclinical autonomic nervous system dysfunctions. These various possible mechanisms should be considered as contributing to diagnostic and treatment algorithms. There is a temptation to label OAB as "idiopathic" without obvious causation, given the poorly understood nature of its pathophysiology. OAB should be seen as a complex, multifactorial symptom syndrome, resulting from multiple potential pathophysiological mechanisms. Identification of the underlying causes on an individual basis may lead to the definition of OAB phenotypes, paving the way for personalised medical care. Overactive bladder (OAB) is a storage symptom syndrome with multiple possible causes. Identification of the mechanisms causing a patient to experience OAB symptoms may help tailor treatment to individual patients and improve outcomes.

Identifiants

pubmed: 30922690
pii: S0302-2838(19)30186-1
doi: 10.1016/j.eururo.2019.02.038
pii:
doi:

Substances chimiques

Gonadal Steroid Hormones 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

988-1000

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Benoit Peyronnet (B)

Department of Urology, University Hospital of Rennes, Rennes, France. Electronic address: peyronnetbenoit@hotmail.fr.

Emma Mironska (E)

Department of Urology, Sheffield Teaching Hospitals, Sheffield, UK.

Christopher Chapple (C)

Department of Urology, Sheffield Teaching Hospitals, Sheffield, UK.

Linda Cardozo (L)

Department of Urology, St. Antonius Hospital, Gronau, Germany.

Matthias Oelke (M)

Department of Urology, Vanderbilt University, Nashville, TN, USA.

Roger Dmochowski (R)

Department of Neurourology, Tenon Hospital, Paris, France.

Gérard Amarenco (G)

Department of Urogynaecology, King's College Hospital, London, UK.

Xavier Gamé (X)

Department of Urology, University Hospital of Toulouse, Toulouse, France.

Roger Kirby (R)

The Prostate Centre, London, UK.

Frank Van Der Aa (F)

Department of Urology, University of Leuven, Leuven, Belgium.

Jean-Nicolas Cornu (JN)

Department of Urology, University Hospital of Rouen, Rouen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH